Literature DB >> 22492462

Deciphering the activation sequence of ferrociphenol anticancer drug candidates.

Pierluca Messina1, Eric Labbé, Olivier Buriez, Elizabeth A Hillard, Anne Vessières, Didier Hamels, Siden Top, Gérard Jaouen, Yves Michel Frapart, Daniel Mansuy, Christian Amatore.   

Abstract

The complete oxidation sequence of a model for ferrociphenols, a new class of anticancer drug candidate, is reported. Cyclic voltammetry was used to monitor the formation of oxidation intermediates on different timescales, thereby allowing the electrochemical characterization of both the short-lived and stable species obtained from the successive electron-transfer and deprotonation steps. The electrochemical preparation of the ferrocenium intermediate enabled a stepwise voltammetric determination of the stable oxidation compounds obtained upon addition of a base as well as the electron stoichiometry observed for the overall oxidation process. A mechanism has been established from the electrochemical data, which involves a base-promoted intramolecular electron transfer between the phenol and the ferrocenium cation. The resulting species is further oxidized then deprotonated to yield a stable quinone methide. To further characterize the transient species successively formed during the two-electron oxidation of the ferrociphenol to its quinone methide, EPR was used to monitor the fate of the paramagnetic species generated upon addition of imidazole to the electrogenerated ferrocenium. The study revealed the passage from an iron-centered to a carbon-centered radical, which is then oxidized to yield the quinone methide, namely, the species that interacts with proteins and so forth under biological conditions.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492462     DOI: 10.1002/chem.201103378

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

1.  ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.

Authors:  Xiaohua Peng; Varsha Gandhi
Journal:  Ther Deliv       Date:  2012-07

2.  Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules.

Authors:  Anne Clavreul; Angélique Montagu; Anne-Laure Lainé; Clément Tétaud; Nolwenn Lautram; Florence Franconi; Catherine Passirani; Anne Vessières; Claudia N Montero-Menei; Philippe Menei
Journal:  Int J Nanomedicine       Date:  2015-02-12

3.  A new generation of ferrociphenols leads to a great diversity of reactive metabolites, and exhibits remarkable antiproliferative properties.

Authors:  Yong Wang; Patrick M Dansette; Pascal Pigeon; Siden Top; Michael J McGlinchey; Daniel Mansuy; Gérard Jaouen
Journal:  Chem Sci       Date:  2017-11-16       Impact factor: 9.825

4.  Synthesis, Electrochemical and Fluorescence Properties of the First Fluorescent Member of the Ferrocifen Family and of Its Oxidized Derivatives.

Authors:  Charles Fayolle; Pascal Pigeon; Nathalie Fischer-Durand; Michèle Salmain; Olivier Buriez; Anne Vessières; Eric Labbé
Journal:  Molecules       Date:  2022-10-08       Impact factor: 4.927

Review 5.  Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors.

Authors:  Pierre Idlas; Elise Lepeltier; Gérard Jaouen; Catherine Passirani
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

6.  Trapping para-Quinone Methide Intermediates with Ferrocene: Synthesis and Preliminary Biological Evaluation of New Phenol-Ferrocene Conjugates.

Authors:  Silvia González-Pelayo; Enol López; Javier Borge; Noemí de-Los-Santos-Álvarez; Luis A López
Journal:  Molecules       Date:  2018-06-01       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.